Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary end-point of this study is to evaluate the objective response rates, and the
secondary end-points are overall survival, progression-free survival and safety profile of
low-dose RAD001 (everolimus) plus cisplatin and HDFL (weekly 24-hour infusion of high-dose
5-FU and leucovorin) chemotherapy in the first-line treatment for patients with unresectable,
recurrent, or metastatic gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
National Cheng-Kung University Hospital Taipei Veterans General Hospital, Taiwan